

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

## **The asymptomatic proportion of SARS-CoV-2 Omicron-variant infections in households: A systematic review**

Nancy DJ Shi<sup>1,\*</sup>, Adrian J Marcato<sup>1,\*</sup>, Violeta Spirkoska<sup>1</sup>, Niamh Meagher<sup>1</sup>, Juan-Pablo Villanueva-Cabezas<sup>1,2</sup>, David J Price<sup>1,3,†</sup>

<sup>1</sup>Department of Infectious Diseases, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, 3000, Australia

<sup>2</sup>The Nossal Institute for Global Health, The University of Melbourne, Melbourne, Victoria, 3000, Australia

<sup>3</sup>Centre for Epidemiology & Biostatistics, Melbourne School of Population & Global Health, The University of Melbourne, Melbourne, Victoria, 3000, Australia

\* These authors contributed equally

† Email correspondence to: [david.price1@unimelb.edu.au](mailto:david.price1@unimelb.edu.au)

## 21 **Abstract**

22

### 23 *Background*

24 Understanding the clinical spectrum of SARS-CoV-2 infection, including the  
25 asymptomatic fraction, is important as asymptomatic individuals are still able to infect  
26 other individuals and contribute to ongoing transmission. The WHO Unity Household  
27 transmission investigation (HHTI) protocol provides a platform for the prospective and  
28 systematic collection of high-quality clinical, epidemiological, serological, and virological  
29 data from SARS-CoV-2 confirmed cases and their household contacts. These data can  
30 be used to understand key severity and transmissibility parameters — including the  
31 asymptomatic proportion — in relation to local epidemic context and help inform public  
32 health response.

33

### 34 *Methods*

35 We aimed to estimate the asymptomatic proportion of SARS-CoV-2 Omicron-variant  
36 infections in Unity-aligned HHTIs. We conducted a systematic review and meta-analysis  
37 in alignment with the PRISMA 2020 guidelines and registered our systematic review on  
38 PROSPERO (CRD42022378648). We searched EMBASE, Web of Science, MEDLINE,  
39 and bioRxiv and medRxiv from 1 November 2021 to 22 August 2023.

40

### 41 *Results*

42 We identified 8,368 records, of which 98 underwent full text review. We identified only  
43 three studies for data extraction, with substantial variation in study design and  
44 corresponding estimates of the asymptomatic proportion. As a result, we did not  
45 generate a pooled estimate or  $I^2$  metric.

### 46 *Conclusions*

47 The limited number of quality studies that we identified highlights the need for improved  
48 preparedness and response capabilities to facilitate robust HHTI implementation,  
49 analysis and reporting, to better inform national, regional and global risk assessments  
50 and policy making.

51

52

53

54

55

56

57

58

59

60

61 **Key words**

62 Asymptomatic proportion, household transmission, SARS-CoV-2, COVID-19

63

64 **Key messages**

65

- 66
- 67 • Estimates for the asymptomatic proportion of SARS-CoV-2 Omicron-variant  
68 infections are highly heterogeneous.
  - 69 • We assessed the proportion of SARS-CoV-2 Omicron-variant infections among  
70 household contacts, who were followed prospectively and systematically, per the  
71 WHO Unity household transmission investigation protocol.
  - 72 • Given the small number of studies with sufficient data and the observed  
73 heterogeneity in the asymptomatic proportion point estimates, we did not provide  
74 a pooled estimate of the asymptomatic proportion.
  - 75 • Fit-for-purpose study designs, and improved reporting, are necessary for robust  
76 estimation of epidemiological characteristics from household studies and their  
77 interpretation.
  - 78 • Ongoing assessment of the asymptomatic proportion of SARS-CoV-2 infection is  
79 critical to inform ongoing public health response options such as testing strategies  
to detect infections and isolation guidance for close contacts.

## 80 Introduction

81

82 Sub-lineages of the SARS-CoV-2 Omicron variant of concern (VOC) continue to  
83 circulate globally and cause significant waves of transmission in the context of hybrid  
84 immunity from coronavirus disease 2019 (COVID-19) vaccination and infection.(1, 2)  
85 Although the Omicron-variant is associated with reduced disease severity relative to  
86 previous variants, it can still cause serious disease due to its ability to evade existing  
87 immunity.(3, 4)

88

89 Studies have shown that the viral load in the upper respiratory tracts of asymptomatic  
90 infected persons is comparable to that of symptomatic individuals, thus these individuals  
91 potentially contribute to onward transmission.(5-7) Asymptomatic individuals may be  
92 less likely to be indicated for or willing to test for infection, and rapid antigen tests  
93 (RATs) have been shown to have reduced diagnostic sensitivity in asymptomatic  
94 persons.(8-10) Further, individuals with asymptomatic infections may be less likely to  
95 practice social or physical distancing measures — due to not knowing they are infected  
96 and potentially infectious — and thus may contribute to the spread of infection in the  
97 general population.(11)

98

99 The asymptomatic proportion among SARS-CoV-2 Omicron-positive individuals has  
100 previously been estimated in two systematic reviews to be 32.4% (95% CI: 25.3–39.5%,  
101  $I^2=97.7%$ ) and 25.5% (95% CI: 17.0–38.2%,  $I^2=100%$ ).(12, 13) Both reviews collated  
102 and synthesised data from various study designs, including cross-sectional studies that  
103 assessed symptom status at a single time point. Cross-sectional studies may lead to  
104 incorrect classification of presymptomatic individuals as asymptomatic — resulting in a  
105 biased estimate of the asymptomatic proportion — and could subsequently contribute to  
106 the high degree of observed heterogeneity when combined with estimates from  
107 sufficient study designs. Inclusion of such studies in a pooled estimate may lead to an  
108 overestimate of the asymptomatic proportion. Such evidence used for informing policy  
109 could lead to suboptimal testing of asymptomatic close contacts.

110

111 In 2020, the World Health Organization (WHO) developed the Unity Studies Early  
112 Investigation Protocols, to generate high-quality data to inform actions at the beginning  
113 of the COVID-19 pandemic.(14) One of the Unity protocols — for household  
114 transmission investigations (HHTIs) — provides a methodology for the systematic  
115 recruitment and longitudinal follow up of laboratory-confirmed SARS-CoV-2 cases and  
116 their household contacts, and collection of clinical, virological and serological data.(15)  
117 Systematic diagnostic testing and symptom data collection are needed to accurately  
118 ascertain infection events necessary to estimate the asymptomatic proportion of SARS-  
119 CoV-2 infection.

120  
121 Our systematic review aimed to collate and synthesise the proportion of asymptomatic  
122 infections amongst household contacts of SARS-CoV-2 Omicron-variant positive cases,  
123 reported in studies aligned with the WHO Unity HHTI protocol. More specifically, we  
124 aimed to: identify and describe the implementation of HHTIs in time and place during  
125 SARS-CoV-2 Omicron-variant outbreaks; assess the methodological quality of included  
126 WHO-aligned HHTIs; calculate a pooled estimate of the asymptomatic proportion of  
127 SARS-CoV-2 Omicron-variant infections amongst household contacts, if appropriate,  
128 and; explore sources of heterogeneity in the included HHTIs.

129  
130

## 131 **Methods**

132  
133 The systematic review protocol was registered on PROSPERO (CRD42022378648)  
134 and was conducted according to the Preferred Reporting Items for Systematic Reviews  
135 and Meta-Analyses (PRISMA) reporting guidelines.(16)

136  
137

### *Definitions*

138  
139 Asymptomatic SARS-CoV-2 infections were defined as infections confirmed through an  
140 appropriate diagnostic test — e.g., reverse transcriptase polymerase chain reaction  
141 (RT-PCR), or rapid antigen test (RAT) — where the individual experienced no  
142 symptoms consistent with the clinical case definition of COVID-19 (as defined by  
143 included studies in Supplementary Table 1). The asymptomatic proportion was defined  
144 as the number of asymptomatic secondary cases amongst all reported secondary cases  
145 in households.

146  
147 Note that we include all cases in our estimate of the asymptomatic proportion besides  
148 the case that triggered recruitment to the study (i.e., the index case) — this was to avoid  
149 the potential bias that would result from a higher propensity for symptoms amongst the  
150 index cases.

151  
152

### *Search strategy*

153  
154 MEDLINE, EMBASE and Web of Science databases were searched to identify articles  
155 published between 1 November 2021 and 22 August 2023. We searched combinations  
156 of COVID-19, asymptomatic, household contacts, and Omicron (including Pango  
157 lineages BA.1, BA.2, BA.4 and BA.5). The medRxiv and bioRxiv preprint servers were  
158 also searched using the same search criteria. The detailed search strategies can be  
159 found in Supplementary Section S.1.

160

161 *Eligibility criteria*

162

163 We included any published (peer-reviewed) or preprint article aligned with the WHO  
164 Unity HHTI protocol, involving five or more households, where household contacts were  
165 systematically tested for SARS-CoV-2 using an appropriate diagnostic test and had  
166 sufficient symptom data collected at more than one time point (i.e., not including cross-  
167 sectional studies). Only articles published in English were included.

168

169 Studies must have reported the proportion of asymptomatic or symptomatic infections  
170 amongst household contacts exposed to an index case of the Omicron-variant with a  
171 measure of uncertainty (e.g., confidence interval) or provided sufficient data to calculate  
172 these parameters.

173

174 *Screening and article selection*

175

176 Records were imported into Covidence for de-duplication, storage, screening, and data  
177 extraction.(17) Records were screened by title and abstract by two independent  
178 reviewers (NS, AM) blinded to each other's assessments, and a third independent  
179 reviewer (VS) resolved any conflicts. The same methods were applied to the full text  
180 screening.

181

182 *Data extraction*

183

184 The following data fields were extracted using a structured and piloted form:  
185 investigation timing and duration of follow-up; definition of "household"; definition of  
186 "asymptomatic infection"; secondary case ascertainment methods; symptom data  
187 collection methods, and the number of index cases, households, household contacts,  
188 secondary cases, and asymptomatic secondary cases.

189

190 Where the reported estimates or definitions were unclear or not provided, study  
191 corresponding authors were contacted to request clarification or additional information.  
192 Investigations were excluded if authors did not respond after two email attempts over a  
193 four-week period.

194

195 *Methodological quality assessment*

196

197 A critical appraisal tool for HHTIs was applied to the included investigations to assess  
198 their methodological quality.(18) Two independent reviewers (NS, AM) applied the  
199 critical appraisal tool and responses for each question were recorded as yes, no, or

200 unclear. Each investigation was then determined to have a high, moderate, or low  
201 overall risk of bias.

202

203 *Data synthesis and statistical analysis*

204 Estimates of the SARS-CoV-2 asymptomatic proportion – and associated 95%  
205 confidence intervals – were extracted from included articles or calculated from the raw  
206 data. Data cleaning and collation was performed using R version 4.0.(19)

207

## 208 **Results**


209

210 Figure 1 summarises the literature search and screening process. We identified 8,368  
211 records from the research databases and preprint servers, of which 3,770 were  
212 duplicates. Full text review was undertaken on 98 records. Three studies met our  
213 inclusion criteria and were retained for data extraction. Details of the reasons for  
214 exclusion are included in Figure 1.

215 The three included studies were all based in the United States of America and were  
216 conducted from November 2021 to March 2022. (20-22)

217 The estimates of the asymptomatic proportion from these three studies vary  
218 substantially, with point estimates of 0%, 6.7% and 47.8% (Figure 2). Further, these  
219 estimates were based on small sample sizes – the largest including 45 secondary  
220 cases. As a result, there is substantial uncertainty in each estimate, with the confidence  
221 intervals spanning 0–69.4%. Given the small number of included studies, we do not  
222 report a pooled estimate. Further, we have not calculated the  $I^2$  metric, due to its  
223 unreliability when the number of studies included is small.(20)

224



225

226 **Figure 1 - PRISMA flow chart.**

227

228

229

230

231

232




233 **Table 1.** Summary characteristics of studies included in the systematic review of the  
 234 asymptomatic proportion of SARS-CoV-2 Omicron-variant infections in households.

Author, Year (ref)	Country	Relevant study period	Case ascertainment methods	Household contact testing strategy	Total number of household secondary cases	Total number of asymptomatic household secondary cases
Smith-Jeffcoat et al., 2022 (21)	United States of America	30 November 2021 – 20 December 2021	RT-PCR and RAT	Unclear <sup>#</sup>	6	0
Bendall et al., 2022 (22)	United States of America	1 November 2021 <sup>+</sup> – 19 January 2022	RT-PCR	1) 'MHome' cohort - Days 0, 5, and 10 after enrolment for all participating household members.  2) 'HIVE' cohort - Days 0, 5, and 10 after the index case diagnosis	23	11
Ji et al., 2023 (23)	United States of America	November 2021 – March 2022	RAT once daily upon enrolment <u>or</u> RT-PCR	Daily upon enrolment	37	3

235 <sup>#</sup> Reported median symptom duration of 13 days among positive household contacts implies longitudinal data collection.

236 <sup>+</sup> Note that this study commenced on November 18, 2020. The reported dates relate to the identification of Omicron-variant  
 237 infections, as relevant to this study.

238



239

240

241 **Figure 2.** Forest plot of the asymptomatic proportion among household secondary  
 242 cases. The estimated asymptomatic proportion and 95% confidence interval (CI) are  
 243 shown on the right. Note: Smith-Jeffcoat et al., has a 97.5% confidence CI as zero  
 244 asymptomatic infection events were observed.

245

246 *Smith-Jeffcoat et al. (2022)*

247 Smith-Jeffcoat et al., (2022) recruited index cases from attendees at a convention in  
248 New York City, USA, which was held between 19 and 21 November 2021.(21) SARS-  
249 CoV-2 infections in attendees were identified using a combination of RT-PCR and  
250 RATs. Although the exact duration of follow-up was unclear, the investigators stated  
251 that median symptom duration was 13 days, implying that participants were followed for  
252 more than 13 days.

253 In total, 16 index cases (households) were identified who had 20 household contacts. Of  
254 these, six became secondary cases — all six cases were symptomatic during their  
255 infection.

256 Most participants — 100% (16/16) of index cases and 95% (19/20) of household  
257 contacts — completed their primary COVID-19 vaccine series more than 14 days prior  
258 to the study. Additionally, 38% (6/16) of index cases and 53% (10/19) of household  
259 contacts had received a booster dose.

260 *Bendall et al. (2022)*

261 Bendall et al., (2022) recruited households in South-East Michigan, USA between  
262 November 1 2021 and January 19 2022.(22) Household were recruited into two cohorts,  
263 known as ‘MHome’ and ‘HIVE’. Participants in both cohorts were tested using RT-PCR  
264 at three timepoints during the investigation on Days 0, 5, and 10 after enrolment  
265 (‘MHome’) or after the index case diagnosis (‘HIVE’).

266 In total, 14 index cases (households) were identified, with 24 household contacts.  
267 Twenty-three household contacts became secondary cases, 11 of which remained  
268 asymptomatic after follow-up.

269 No vaccination information of householders was provided, however, 54.4% of the  
270 population in Michigan had completed their primary series of COVID-19 vaccinations by  
271 November 2021.(24)

272 *Ji et al. (2023)*

273 Ji et al., (2023) recruited households through the California Institute of Technology in  
274 California, USA, between November 2021 and March 2022.(23) Only household  
275 members aged 6 years and older were included. Household contacts were tested daily  
276 using RATs as well as providing symptom information. 96% of participants were  
277 screened for at least 5 days and 53% were enrolled for at least 9 days.

278 In total, 28 index cases (households) were identified. An additional five households  
279 were recruited, where the infecting SARS-CoV-2 variant was inferred to be Omicron

280 based on local predominance. The 33 index cases were associated with 130 household  
281 contacts (of which 109 related to the Omicron-variant confirmed households). Forty-five  
282 household contacts of Omicron-variant confirmed cases became secondary cases, and  
283 out of 37 secondary cases with complete symptom data, three remained asymptomatic  
284 until the end of follow-up.

285 31.3% (51/163) of participants (Omicron confirmed and inferred) received their primary  
286 COVID-19 vaccine series more than 7 days prior to the study, with 44.2% (72/163)  
287 receiving an additional booster dose. A further 3.7% (6/163) of participants were either  
288 unvaccinated or partially vaccinated (one dose), and the vaccination status was  
289 unknown for 20.9% (34/163) of participants. The incomplete symptom and vaccination  
290 status data was attributed to incomplete household recruitment, such that enrolled  
291 householders reported on the symptom status of their household members who chose  
292 not to directly participate.

293

## 294 **Discussion**

295 This is the first systematic review investigating the asymptomatic proportion of SARS-  
296 CoV-2 infections in Unity-aligned HHTI studies. We identified three studies conducted in  
297 the United States from late-2021 to early-2022, with sufficient longitudinal follow-up and  
298 specimen sampling from household contacts. Effective control of an infectious disease  
299 requires identification and appropriate management of infectious individuals to prevent  
300 transmission. Infectious individuals not presenting with symptoms or meeting the clinical  
301 criteria of a case definition are typically harder to identify, and thus manage. As such,  
302 quantifying the prevalence of asymptomatic infections is critical to inform effective  
303 management strategies that do not rely on the presence of symptoms alone.(25)

304 The point estimates of the asymptomatic proportion ranged from 0–47.8%. Previously  
305 published systematic reviews produced pooled estimates of the asymptomatic  
306 proportion among SARS-CoV-2 Omicron-positive individuals of 32.4% (95% CI: 25.3–  
307 39.5%) and 25.5% (95% CI: 17.0–38.2%), despite noting high levels of heterogeneity.  
308 The point estimates of included studies ranged from 1–92%,  $I^2 = 97.7\%$  and 4–40%,  $I^2 =$   
309 100%.(12, 13) As noted above, we do not report a pooled estimate or  $I^2$  metric.

310 Two earlier systematic reviews of the ancestral SARS-CoV-2 strain, both published in  
311 2020, by *Buitrago-Garcia et al.* (26) and *Byambasuren et al.* (27), included 79 and 13  
312 outbreak or contact tracing studies respectively, to produce a pooled estimate of the  
313 asymptomatic proportion. The included studies in each review were highly  
314 heterogenous, with estimates for the asymptomatic proportion ranging from 1–92%  
315 (pooled estimate of 19%, 95% CI: 17–25%), and from 4–40% (pooled estimate of 17%,  
316 95% CI: 14–20%).(26, 27) Although cross-sectional studies were excluded from

317 evidence synthesis in these reviews, the extent of heterogeneity as measured by  $I^2$   
318 remained high (84% in (27)).

319 It is crucial to understand and contextualise the differences between studies prior to  
320 pooling estimates, to ensure each study is providing quality information towards the  
321 same quantity. This includes differences in study design (e.g., frequency and method of  
322 testing and symptom data collection), as well as any differences in population-level  
323 susceptibility (e.g., age-specific differences, or protection acquired through COVID-19  
324 vaccination and/or SARS-CoV-2 infection), or public health and social measures (e.g.,  
325 physical distancing or use of PPE and testing accessibility), that may influence detection  
326 of infection and extent of clinical disease. It may be that these differences contributed to  
327 the heterogeneity we observed in our three included studies.

328 We focused on household studies as a subset of the literature and thus had fewer  
329 studies suitable for inclusion, where previous reviews covered a broader range of study  
330 designs. The abundance of literature early in the pandemic was likely due to the  
331 global need to accurately characterise the emerging virus as early as possible. Further,  
332 the expansion of testing and contact tracing capacities in 2020 and 2021 (prior to  
333 widespread COVID-19 vaccination) would have enabled or improved capacity for  
334 conducting studies with systematic testing and follow-up of close contacts, including  
335 HHTIs.

336 Subsequently, public health strategies shifted to impose less stringent PHSMs than had  
337 been implemented to-date, relying instead on effective vaccines against disease to  
338 reduce the burden of COVID-19. The substantial increase in caseloads corresponding  
339 to the spread of the Omicron-variant overwhelmed public health systems,(28) reducing  
340 the ability to implement the level of detailed contact-tracing required to generate data for  
341 ongoing characterisation of COVID-19, including the asymptomatic proportion. This shift  
342 in priorities was reflected in the literature during our full text review. Many excluded  
343 records did not estimate or report the asymptomatic proportion or have sufficient follow-  
344 up or testing strategies to reliably do so. Instead, they often focussed on the effect of  
345 vaccination on SARS-CoV-2 transmission dynamics, including estimates of secondary  
346 attack rates and vaccine effectiveness.

347 More generally, during the early stages of the pandemic, journals helped to expedite  
348 COVID-19 research to rapidly and widely disseminate information needed to address  
349 the global public health crisis. Our search strategy included articles published to 23  
350 October 2023. Despite nearly being two years since the emergence of Omicron, we only  
351 found three relevant articles in the literature, which were all conducted in late-2021 to  
352 early-2022. In addition to changes in public health priorities and capacity to conduct  
353 HHTIs, changes in the dissemination of COVID-19 studies in scientific journals may  
354 have also delayed the availability of other, relevant studies at the time of this review. We

355 tried to account for delays in publication as the pandemic progressed by searching the  
356 medRxiv and bioRxiv pre-print servers, which were commonly used to rapidly  
357 disseminate articles prior to publication.

358 While we targeted Unity-aligned studies in our review with the aim of improving  
359 comparability of studies, there were still differences present in the design and  
360 implementation of included studies. For example, age-specific severity and duration of  
361 follow-up are both important aspects for measuring and estimating severity indicators,  
362 including the asymptomatic fraction. Age-dependent severity has been documented  
363 extensively for SARS-CoV-2 infections since the ancestral variant.(29) However,  
364 reporting of severity indicators such as the asymptomatic fraction, are not routinely  
365 adjusted by age – including in the studies in this review. Further, one study did not  
366 include children under 6 years of age. The absence of age-adjusted information — and  
367 other underlying characteristics and/or risk factors — makes it challenging to explore  
368 whether differences in cohorts across studies are substantial contributors to the  
369 heterogeneity in reported estimates of the asymptomatic fraction. The follow-up duration  
370 differed across the three studies — between 5 and at least 13-days post-recruitment of  
371 the index case — as well as the frequency of testing and collection of symptom status.  
372 The incubation period for the Omicron-variant of SARS-CoV-2 has since been  
373 estimated in many studies (30-32) — one estimated the median incubation period to be  
374 3.8 days (95%CrI 3.5–4.1).(30) If this distribution was observed in participants in our  
375 study, it would be expected that only 82.5% (95%CI 75.5–88.1) of secondary cases  
376 would present with symptoms by day 5 were they infected at recruitment (and less if  
377 infected thereafter). Further, while we defined inclusion based on individuals being  
378 classified as secondary cases, the literature often did not distinguish secondary and  
379 subsequent cases (or unrelated cases) in transmission chains. As a result, there is an  
380 increased likelihood that our included studies still incorrectly classified individuals as  
381 pre-symptomatic. The design of transmission studies (including HHTIs) to infer  
382 epidemiological characteristics of a pathogen should consider the range of possible  
383 values each quantity could take. In the case of the asymptomatic fraction, study design  
384 should consider the generation interval distribution and incubation period distribution to  
385 ensure that participants that are infected (possibly after recruitment given ongoing  
386 exposure to cases) are followed for sufficiently long to accurately record their symptom  
387 status throughout their infection. Where this information is unknown at the time, a  
388 conservative approach to defining a sufficient length of follow up should be taken to  
389 avoid resources wastage where quantities cannot be estimated due to an inappropriate  
390 study design.

391 In light of lessons learned through the COVID-19 pandemic thus far, WHO have  
392 released updated Unity protocols for influenza and pan-respiratory viruses.(33, 34) The  
393 sampling schedules therein correlate with biological and epidemiological quantities of

394 each exemplar pathogen to guide appropriate data and specimen collection to inform  
395 classification of subsequent cases. Modelling studies accounting for uncertainty in these  
396 quantities in different pathogen scenarios should be undertaken to inform optimal  
397 sampling schedules.(35-37)

398 The heterogeneous evidence for the asymptomatic proportion used in existing  
399 systematic reviews for ancestral SARS-CoV-2 and Omicron suggests that study designs  
400 still need to be standardised for better implementation and reporting across different  
401 settings and populations. This is a consistent message with a recent review of the  
402 household secondary attack rate,(38) where similar limitations in study design and  
403 reporting were identified, which motivated the development of reporting guidelines and  
404 updates to the WHO protocols.(18, 33, 34)

405 Although the Unity Studies were motivated to produce early generation of evidence for  
406 COVID-19, HHTIs should be used to support ongoing monitoring of epidemiological  
407 quantities as the COVID-19 pandemic evolves, e.g., during the emergence of Omicron  
408 subvariants or new VOCs. Ongoing assessment of these quantities is critical so that  
409 public health response options such as testing strategies to detect infections and  
410 isolation guidance for close contacts, can be adjusted accordingly.

## 411 **Conclusion**

412 HHTIs remain a valuable tool to collect data and collate information on key clinical and  
413 epidemiological data of COVID-19, especially given the continued evolution of SARS-  
414 CoV-2. The limited number of quality studies that we identified highlights the need for  
415 improved preparedness and response capabilities to facilitate robust HHTI  
416 implementation, analysis and reporting, to better inform national, regional and global  
417 risk assessments and policy making.

418

## 419 **Ethics approval**

420 Not required

## 421 **Data availability**

422 The data underlying this article are available in the article and in its online  
423 supplementary material.

## 424 **Supplementary Data**

425 Supplementary data are available at *IJE* online.

## 426 **Author contributions**

427 The authors confirm contribution to the paper as follows: study conceptualisation and  
428 methodology – all; investigation — NDJS, AM, VS; data curation — NDJS, AM;  
429 visualization — NDJS, AM, DJP; supervision — AM, VS, JPVC, DJP; writing – original  
430 draft — NDJS, AM, DJP. All authors reviewed and edited the draft manuscript and  
431 approved the final version for publication.

## 432 **Funding**

433 AJM and DJP are supported by funding from Australian National Health and Medical  
434 Research Council Partnership (#1195895).

## 435 **Conflict of interest**

436 None to declare.

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

## 456 References

- 457 1. Hodcroft EB. CoVariants: SARS-CoV-2 Mutations and Variants of Interest 2021  
458 [15 April 2024]. Available from: <https://covariants.org/>.
- 459 2. World Health Organization. WHO COVID-19 Dashboard 2024 [15 April 2024].  
460 Available from: <https://data.who.int/dashboards/covid19/cases?n=0>.
- 461 3. Bálint G, Vörös-Horváth B, Széchenyi A. Omicron: increased transmissibility and  
462 decreased pathogenicity. *Signal Transduction and Targeted Therapy*. 2022;7(1):151.
- 463 4. Relan P, Motaze NV, Kothari K, Askie L, Le Polain O, Van Kerkhove MD, et al.  
464 Severity and outcomes of Omicron variant of SARS-CoV-2 compared to Delta variant  
465 and severity of Omicron sublineages: a systematic review and meta-analysis. *BMJ Glob  
466 Health*. 2023;8(7).
- 467 5. Wu Q, Shi L, Li H, Huang S, Li H, Li L, et al. Viral RNA Load in Symptomatic and  
468 Asymptomatic COVID-19 Omicron Variant-Positive Patients. *Can Respir J*.  
469 2022;2022:5460400.
- 470 6. Jiang L, Tang L, Zhu L, Zhu Y, Yang S, Chen W, et al. Viral dynamics during  
471 SARS-CoV-2 omicron infection highlight presymptomatic and asymptomatic  
472 infectiousness. *J Infect*. 2023;86(5):537-9.
- 473 7. Bae S, Kim JY, Lim SY, Park H, Cha HH, Kwon JS, et al. Dynamics of Viral  
474 Shedding and Symptoms in Patients with Asymptomatic or Mild COVID-19. *Viruses*.  
475 2021;13(11).
- 476 8. Fernandez-Montero A, Argemi J, Rodríguez JA, Ariño AH, Moreno-Galarraga L.  
477 Validation of a rapid antigen test as a screening tool for SARS-CoV-2 infection in  
478 asymptomatic populations. Sensitivity, specificity and predictive values.  
479 *EClinicalMedicine*. 2021;37:100954.
- 480 9. Venekamp RP, Schuit E, Hooft L, Veldhuijzen IK, van den Bijllaardt W, Pas SD,  
481 et al. Diagnostic accuracy of SARS-CoV-2 rapid antigen self-tests in asymptomatic  
482 individuals in the omicron period: a cross-sectional study. *Clinical Microbiology and  
483 Infection*. 2023;29(3):391.e1-.e7.
- 484 10. Schuetz Audrey N, Hemarajata P, Mehta N, Campbell S, Mitchell S, Palavecino  
485 E, et al. When Should Asymptomatic Persons Be Tested for COVID-19? *Journal of  
486 Clinical Microbiology*. 2020;59(1):10.1128/jcm.02563-20.
- 487 11. Johansson MA, Quandelacy TM, Kada S, Prasad PV, Steele M, Brooks JT, et al.  
488 SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. *JAMA Network  
489 Open*. 2021;4(1):e2035057-e.
- 490 12. Shang W, Kang L, Cao G, Wang Y, Gao P, Liu J, et al. Percentage of  
491 Asymptomatic Infections among SARS-CoV-2 Omicron Variant-Positive Individuals: A  
492 Systematic Review and Meta-Analysis. *Vaccines (Basel)*. 2022;10(7).
- 493 13. Yu W, Guo Y, Zhang S, Kong Y, Shen Z, Zhang J. Proportion of asymptomatic  
494 infection and nonsevere disease caused by SARS-CoV-2 Omicron variant: A systematic  
495 review and analysis. *J Med Virol*. 2022;94(12):5790-801.
- 496 14. World Health Organization. Coronavirus disease (COVID-19) technical guidance:  
497 The Unity Studies: Early Investigation Protocols  
498 2020 [15 April 2024]. Available from: [https://www.who.int/emergencies/diseases/novel-  
499 coronavirus-2019/technical-guidance/early-investigations](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/early-investigations).



- 500 15. World Health Organization. Household transmission investigation protocol for  
501 coronavirus disease (COVID-19), version 2.2 2021 [15 April 2024]. Available from:  
502 [https://www.who.int/publications/i/item/household-transmission-investigation-protocol-](https://www.who.int/publications/i/item/household-transmission-investigation-protocol-for-2019-novel-coronavirus-(2019-ncov)-infection)  
503 [for-2019-novel-coronavirus-\(2019-ncov\)-infection](https://www.who.int/publications/i/item/household-transmission-investigation-protocol-for-2019-novel-coronavirus-(2019-ncov)-infection).
- 504 16. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al.  
505 The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.  
506 *BMJ*. 2021;372:n71.
- 507 17. Covidence systematic review software VHI, Melbourne, Australia. [Available  
508 from: [www.covidence.org](http://www.covidence.org).
- 509 18. Price DJ, Spirkoska V, Marcato AJ, Meagher N, Fielding JE, Karahalios A, et al.  
510 Household transmission investigation: Design, reporting and critical appraisal. *Influenza*  
511 *and Other Respiratory Viruses*. 2023;17(6):e13165.
- 512 19. R Core Team. R: A language and environment for statistical computing. R  
513 Foundation for Statistical Computing, Vienna, Austria. 2021.
- 514 20. von Hippel PT. The heterogeneity statistic I<sup>2</sup> can be biased in small meta-  
515 analyses. *BMC Medical Research Methodology*. 2015;15(1):35.
- 516 21. Smith-Jeffcoat S, Pomeroy M, Sleweon S, Sami S, Ricaldi J, Gebru Y, et al.  
517 Multistate Outbreak of SARS-CoV-2 B.1.1.529 (Omicron) Variant Infections Among  
518 Persons in a Social Network Attending a Convention — New York City, November 18–  
519 December 20, 2021. *MMWR Morbidity and Mortality Weekly Report*. 2022;71:238-42.
- 520 22. Bendall EE, Callear AP, Getz A, Goforth K, Edwards D, Monto AS, et al. Rapid  
521 transmission and tight bottlenecks constrain the evolution of highly transmissible SARS-  
522 CoV-2 variants. *Nat Commun*. 2023;14(1):272.
- 523 23. Ji J, Vilorio Winnett A, Shelby N, Reyes JA, Schlenker NW, Davich H, et al. Index  
524 cases first identified by nasal-swab rapid COVID-19 tests had more transmission to  
525 household contacts than cases identified by other test types. *PLOS ONE*.  
526 2023;18(10):e0292389.
- 527 24. Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA:  
528 U.S. Department of Health and Human Services, CDC 2024 [15 April 2024]. Available  
529 from: <https://covid.cdc.gov/covid-data-tracker/#vaccination-demographics-maps>.
- 530 25. Montgomery MP, Morris SE, Rolfes MA, Kittikraisak W, Samuels AM, Biggerstaff  
531 M, et al. The role of asymptomatic infections in influenza transmission: what do we  
532 really know. *The Lancet Infectious Diseases*.
- 533 26. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM,  
534 et al. Occurrence and transmission potential of asymptomatic and presymptomatic  
535 SARS-CoV-2 infections: A living systematic review and meta-analysis. *PLOS Medicine*.  
536 2020;17(9):e1003346.
- 537 27. Byambasuren O, Cardona M, Bell K, Clark J, McLaws ML, Glasziou P.  
538 Estimating the extent of asymptomatic COVID-19 and its potential for community  
539 transmission: Systematic review and meta-analysis. *J Assoc Med Microbiol Infect Dis*  
540 *Can*. 2020;5(4):223-34.
- 541 28. World Health Organization. Contact tracing and quarantine in the context of  
542 the Omicron SARS-CoV-2 variant. 2022.
- 543 29. Variation in the COVID-19 infection-fatality ratio by age, time, and geography  
544 during the pre-vaccine era: a systematic analysis. *The Lancet*. 2022;399(10334):1469-  
545 88.

- 546 30. Xin H, Wang Z, Feng S, Sun Z, Yu L, Cowling BJ, et al. Transmission dynamics  
547 of SARS-CoV-2 Omicron variant infections in Hangzhou, Zhejiang, China, January-  
548 February 2022. *Int J Infect Dis.* 2023;126:132-5.
- 549 31. Galmiche S, Cortier T, Charmet T, Schaeffer L, Chény O, von Platen C, et al.  
550 SARS-CoV-2 incubation period across variants of concern, individual factors, and  
551 circumstances of infection in France: a case series analysis from the ComCor study.  
552 *The Lancet Microbe.* 2023;4(6):e409-e17.
- 553 32. Zeng K, Santhya S, Soong A, Malhotra N, Pushparajah D, Thoon KC, et al.  
554 Serial Intervals and Incubation Periods of SARS-CoV-2 Omicron and Delta Variants,  
555 Singapore. *Emerg Infect Dis.* 2023;29(4):814-7.
- 556 33. World Health Organization. Influenza Investigations & Studies (Unity Studies)  
557 2023 [Available from: [https://www.who.int/teams/global-influenza-](https://www.who.int/teams/global-influenza-programme/surveillance-and-monitoring/influenza-investigations-studies-unity)  
558 [programme/surveillance-and-monitoring/influenza-investigations-studies-unity](https://www.who.int/teams/global-influenza-programme/surveillance-and-monitoring/influenza-investigations-studies-unity).  
559 34. World Health Organization. Respiratory Investigations and Studies (Unity  
560 Studies) 2023 [Available from: [https://www.who.int/initiatives/respiratory-pathogens-](https://www.who.int/initiatives/respiratory-pathogens-investigations-and-studies-unity-studies)  
561 [investigations-and-studies-unity-studies](https://www.who.int/initiatives/respiratory-pathogens-investigations-and-studies-unity-studies).  
562 35. Cope RC, Ross JV. Identification of the relative timing of infectiousness and  
563 symptom onset for outbreak control. *Journal of Theoretical Biology.* 2020;486:110079.
- 564 36. Klick B, Leung GM, Cowling BJ. Optimal design of studies of influenza  
565 transmission in households. I: Case-ascertained studies. *Epidemiology and Infection.*  
566 2012;140(1):106-14.
- 567 37. Lydeamore MJ, Campbell PT, Price DJ, Wu Y, Marcato AJ, Cuninghame W, et al.  
568 Estimation of the force of infection and infectious period of skin sores in remote  
569 Australian communities using interval-censored data. *PLOS Computational Biology.*  
570 2020;16(10):e1007838.
- 571 38. Lewis HC, Marcato AJ, Meagher N, Valenciano M, Villanueva-Cabezas JP,  
572 Spirkoska V, et al. Transmission of SARS-CoV-2 in standardised first few X cases and  
573 household transmission investigations: A systematic review and meta-analysis.  
574 *Influenza Other Respir Viruses.* 2022;16(5):803-19.

